StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Genotropin (somatropin by Quarter

Genotropin (somatropin — growth hormone) — U.S. reported YoY (%) (%)

QuarterlyAnnual

Pfizer Genotropin (somatropin: -89.0% in Q2 2026, down 52.0 pts from a year earlier. That is the lowest of the 28 quarters on record here.

Latest, Q2 2026
-89.0%
Period ended Jun 28, 2026
Change on a year earlier
-52.0 pts
-37.0% in Q2 2025
History
28 quarters
Since Q4 2017
Sources
28
Documents cited below

Where the Q2 2026 figure comes from

“|| Genotropin | 94 | 106 | (11%) | (15%) | 2 | 18 | (89%) | 92 | 89 | 4% | —”

Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗

Reported in Form 8-K Revenue Tables.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedGenotropin (somatropin — growth hormone) — U.S. reported YoY (%) (%)Year on yearSource
Q2 2026Jun 28, 2026-89.0%-52.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2026Mar 29, 202616.0%–Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2025Dec 31, 202581.0%+159.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2025Sep 28, 202514.0%+64.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2025Jun 29, 2025-37.0%–Form 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗
Q4 2024Dec 31, 2024-78.0%-153.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
Q3 2024Sep 29, 2024-50.0%–Form 8-K (Earnings / Guidance Release) (pfe-9292024xex99.htm, filed 2024-10-29) ↗
Q1 2024Mar 31, 2024-55.0%–Form 8-K (Earnings / Guidance Release) (pfe-3312024xex99.htm, filed 2024-05-01) ↗
Q4 2023Dec 31, 202375.0%+68.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Q4 2022Dec 31, 20227.0%+37.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗
Q3 2022Oct 2, 202212.0%+67.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-10022022xex99.htm, filed 2022-11-01) ↗
Q2 2022Jul 3, 2022-53.0%-86.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-07032022xex99.htm, filed 2022-07-28) ↗
Q1 2022Apr 3, 202262.0%+148.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-04032022xex99.htm, filed 2022-05-03) ↗
Q4 2021Dec 31, 2021-30.0%+11.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗
Q3 2021Oct 3, 2021-55.0%-18.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-10032021xex99.htm, filed 2021-11-02) ↗
Q2 2021Jul 4, 202133.0%+18.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-07042021xex99.htm, filed 2021-07-28) ↗

Cite this data

StockData. (2026). Pfizer Genotropin (somatropin (%), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/genotropin-yoy-us

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.